Soligenix Says FDA Grants Type A Meeting Regarding New Drug Application For HyBryte

(RTTNews) - Biopharmaceutical company Soligenix, Inc. (SNGX) announced Monday that the U.S. Food and Drug Administration (FDA) has granted a Type A meeting to discuss the contents of a refusal to file (RTF) letter previously issued regarding the Company's new drug application (NDA) for HyBryte (synthetic hypericin) in the treatment of early stage cutaneous T-cell lymphoma (CTCL), a rare cancer.

The company has successfully demonstrated statistically significant results in a Phase 3 clinical trial.

The company said it intends to provide a further update once it receives the minutes from the meeting or when it has more clarity on next steps, which is anticipated by or before the end of April.

For More Such Health News, visit rttnews.com